FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...

Geron Co. (NASDAQ:GERN – Get Free Report) hit a new 52-week low during trading on Wednesday .The stock traded as low as $1.45 and last traded at $1.48, with a volume of 31179782 shares trading hands ...

Geron (GERN) Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the treatment of adult patients with transfusion-dependent ...